CAMBRIDGE, Mass. and MENLO PARK, Calif.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Depomed, Inc. (NASDAQ: DEPO) today announced that Ironwood has licensed worldwide rights to utilize Depomed’s Acuform™ gastric retentive drug delivery technology for an Ironwood early stage development program, continuing Ironwood’s efforts to augment its development pipeline beyond linaclotide. Under the terms of the agreement, Depomed will assist with initial product formulation and Ironwood will be responsible for all development and commercialization of the product. Depomed will be paid an upfront license fee and will receive additional payments pending achievement of certain development and regulatory milestones, as well as royalties on product sales.
